Phase II Cancer Vaccine Trial for Patients With Follicular Lymphoma

Sponsor
Oslo University Hospital
Study ID
NCT01926639
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Radiotherapy, rituximab and DC — BIOLOGICAL
    Lymphoma lymph nodes are irradiated with 8 Gy single treatment and injected with rituximab (5 mg) and autologous DC intratumorally. The treatment is performed 3 times targeting different lymph nodes

Study Details

Patients with non-curable disseminated follicular lymphoma receive local radiotherapy targeting single lymph nodes and injection of low-dose rituximab (anti-CD20) and autologous dendritic cells. The therapy is repeated 3 times, targeting different lesion. Aims are to induce tumor immunity and clinical responses.

Key Dates

Start date
Oct 31, 2009
Status verified
Oct 2014
Primary completion
Oct 31, 2014
Completion
Oct 31, 2014

Study Design

Enrollment
14 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Radiotherapy , rituximab and DC
    Treatment repeated 3 times and targeting different lymph nodes

Primary Outcome Measure

Response rate [ Time Frame: 5 years ]

Related Studies